10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript Bruker Non-GAAP EPS of $0.53 beats by $0.07, revenue of $721.7M misses by $7.34M Bruker Q1 2024 Earnings Preview ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Across the recent three months, 6 analysts have shared their insights on 10x Genomics (NASDAQ:TXG), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.

EST Cathie Wood’s ARK Investment buys 370K shares of 10x Genomics (TXG) todayInvest with Confidence: Follow TipRanks' Top Wall Street ...